$2.70
4.93% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

VYNE Therapeutics Inc Stock price

$2.70
+0.70 35.00% 1M
-0.06 2.17% 6M
+0.37 15.88% YTD
-1.42 34.47% 1Y
-20.34 88.28% 3Y
-311.22 99.14% 5Y
-2,064.42 99.87% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.14 4.93%
ISIN
US92941V1008
Symbol
VYNE
Sector
Industry

Key metrics

Market capitalization $39.83m
Enterprise Value $-30.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.01
EV/Sales (TTM) EV/Sales -61.80
P/S ratio (TTM) P/S ratio 81.29
P/B ratio (TTM) P/B ratio 0.63
Revenue growth (TTM) Revenue growth 39.27%
Revenue (TTM) Revenue $490.00k
EBIT (operating result TTM) EBIT $-37.70m
Free Cash Flow (TTM) Free Cash Flow $-30.11m
Cash position $70.23m
EPS (TTM) EPS $-0.85
P/E forward 0.10
P/S forward 76.16
EV/Sales forward negative
Short interest 0.34%
Show more

Is VYNE Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

VYNE Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a VYNE Therapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a VYNE Therapeutics Inc forecast:

Buy
100%

Financial data from VYNE Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.49 0.49
40% 40%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
5% 5%
2,839%
- Research and Development Expense 24 24
38% 38%
4,957%
-38 -38
23% 23%
-7,694%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -38 -38
24% 24%
-7,694%
Net Profit -34 -34
6% 6%
-6,935%

In millions USD.

Don't miss a Thing! We will send you all news about VYNE Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VYNE Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 months ago
BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose (“SAD”) portion of its ongoing Phase 1a tria...
Neutral
GlobeNewsWire
3 months ago
BRIDGEWATER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and six months ended June 30, 2024 and provided ...
Neutral
GlobeNewsWire
5 months ago
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
More VYNE Therapeutics Inc News

Company Profile

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

Head office United States
CEO David Domzalski
Employees 10
Founded 2011
Website www.vynetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today